European Notebook: EMA Public Hearings Soon; Patient Data Rules Welcomed; Bayer Battles German HTA
Executive Summary
Europe’s regulator lays out rules for public meetings of its advisory committees, and the region's new data protection legislation will allow one-time patient consent, smoothing the transfer of data; Bayer is the latest company to be upset over Germany’s HTA process.
You may also be interested in...
EMA's New PRIME Scheme Gets 18 Applications In First Month
Eleven applications to the European priority review program came from smaller companies.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.